✦ LIBER ✦

A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes

✍ Scribed by P. D. Home; R. Rosskamp; J. Forjanic-Klapproth; A. Dressler

Publisher: John Wiley and Sons
Year: 2005
Tongue: English
Weight: 176 KB
Volume: 21
Category: Article
ISSN: 1520-7552
DOI: 10.1002/dmrr.572

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

An observational study comparing continu

An observational study comparing continuous subcutaneous insulin infusion (CSII) and insulin glargine in children with type 1 diabetes

✍ Riccardo Schiaffini; Paolo Ciampalini; Sabrina Spera; Marco Cappa; Antonino Crin 📂 Article 📅 2005 🏛 John Wiley and Sons 🌐 English ⚖ 103 KB

Comparison of insulin detemir and insuli

Comparison of insulin detemir and insulin glargine using a basal-bolus regimen in a randomized, controlled clinical study in patients with type 2 diabetes

✍ Philip Raskin; Titus Gylvin; Wayne Weng; Louis Chaykin 📂 Article 📅 2009 🏛 John Wiley and Sons 🌐 English ⚖ 121 KB

How diabetes and insulin therapy affects

How diabetes and insulin therapy affects the lives of people with type 1 diabetes

✍ B Nafees; A Lloyd; T Kennedy-Martin; S Hynd 📂 Article 📅 2006 🏛 Maney Publishing 🌐 English ⚖ 185 KB 👁 1 views

Severe hypoglycaemia in patients with ty

Severe hypoglycaemia in patients with type 1 diabetes and impaired awareness of hypoglycaemia: a comparative study of insulin lispro and regular human insulin

✍ Stewart C. Ferguson; Mark W. J. Strachan; Jonathan M. Janes; Brian M. Frier 📂 Article 📅 2001 🏛 John Wiley and Sons 🌐 English ⚖ 90 KB

Combined bedtime insulin–daytime sulphon

Combined bedtime insulin–daytime sulphonylurea regimen compared with two different daily insulin regimens in type 2 diabetes: effects on HbA1c and hypoglycaemia rate—a randomised trial

✍ M. H. A. Stehouwer; J. H. DeVries; J. A. E. Lumeij; H. J. Adèr; A. M. S. Engbers 📂 Article 📅 2003 🏛 John Wiley and Sons 🌐 English ⚖ 84 KB

Pravastatin compared to bezafibrate in t

Pravastatin compared to bezafibrate in the treatment of dyslipidemia in insulin-treated patients with Type 2 diabetes mellitus

✍ C. Rustemeijer; J. A. Schouten; H. J. Voerman; H. E. S. J. Hensgens; A. J. M. Do 📂 Article 📅 2000 🏛 John Wiley and Sons 🌐 English ⚖ 99 KB 👁 2 views

Background Both HMG-CoA reductase inhibitors and ®bric acid derivates are used for the treatment of dyslipidemia in Type 2 diabetes patients. The aim of this study was to compare the lipid lowering effect of 40 mg pravastatin, a HMG-CoA reductase inhibitor, and 400 mg beza®brate, a ®bric acid deriva